|
| 37097747 | Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms. | | 2023 |
| 37678251 | Menopause-Biology, consequences, supportive care, and therapeutic options. | Cell | 2023 |
| 38032827 | Hormonal Medications for Genitourinary Syndrome of Menopause. | | 2023 |
| 34693971 | Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency? | J Clin Endocrinol Metab | 2022 |
| 35594471 | Concerns About Compounded Bioidentical Menopausal Hormone Therapy. | Cancer journal (Sudbury, Mass.) | 2022 |
| 35998670 | Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer. | Menopause | 2022 |
| 35980244 | Multidisciplinary Management of Menopause: Symposium Proceedings. | Journal of Women's Health | 2022 |
| 34310353 | Selective Estrogen Receptor Modulators in Gynecology Practice. | Clinical Obstetrics and Gynecology | 2021 |
| 34127630 | Concerns about safety and efficacy of compounded bioidentical hormone therapy. | Menopause | 2021 |
| 33518182 | Risks of Testosterone for Postmenopausal Women. | | 2021 |
| 33110032 | The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy. | Menopause | 2020 |
| 32379215 | Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. | Menopause | 2020 |
| 32187132 | Hormone therapy and sarcopenia: implications for the prevention of frailty as women age. | Menopause | 2020 |
| 32067815 | Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Meno | Gynecologic Oncology | 2020 |
| 32345788 | The Women's Health Initiative trials of menopausal hormone therapy: lessons learned. | Menopause | 2020 |
| 32052007 | Underlying Breast Cancer Risk and Menopausal Hormone Therapy. | J Clin Endocrinol Metab | 2020 |
| 31995690 | Hormone Therapy for Postmenopausal Women. | New England Journal of Medicine | 2020 |
| 32459749 | Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. | Menopause | 2020 |
| 32882039 | Approach to Managing a Postmenopausal Patient. | J Clin Endocrinol Metab | 2020 |
| 32521153 | Hormone Therapy for Postmenopausal Women. Reply. | New England Journal of Medicine | 2020 |
| 32852466 | In Reply. | Menopause | 2020 |
| 31498871 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | J Clin Endocrinol Metab | 2019 |
| 30399025 | Assessment of NAMS members' prescription patterns of hormone therapy before and after the 2016 NAMS Annual Meeting. | Menopause | 2019 |
| 30260548 | Hormone therapy does not impact long-term all-cause mortality. | BJOG: An International Journal of Obstetrics and Gynaecology | 2019 |
| 30098845 | Vaginal estrogen: Underprescribed treatment for an underdiagnosed condition of menopausal women. | | 2019 |
| 31503029 | Management of Menopause and the Role For Hormone Therapy. | Clinical Obstetrics and Gynecology | 2019 |
| 31081391 | Managing vasomotor symptoms in women after cancer. | Climacteric | 2019 |
| 31488288 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | J Sex Med | 2019 |
| 31474158 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | Climacteric | 2019 |
| 31484631 | Global Consensus Position Statement on the use of Testosterone Therapy for Women. | Maturitas | 2019 |
| 30895900 | Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. | Climacteric | 2019 |
| 30789455 | Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy. | Menopause | 2019 |
| 30714849 | Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications. | Journal of Women's Health | 2019 |
| 29064335 | Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. | Journal of Women's Health | 2018 |
| 29889667 | Hormone Therapy: Key Points From NAMS 2017 Position Statement. | Clinical Obstetrics and Gynecology | 2018 |
| 29889666 | Foreword: Managing Menopause by Combining Evidence With Clinical Judgment. | Clinical Obstetrics and Gynecology | 2018 |
| 29870471 | The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. | Menopause | 2018 |
| 29957102 | Why Should Clinicians Be Concerned About Prescribing Compounded Hormones for Menopausal Women? | Journal of Women's Health | 2018 |
| 29851863 | Tissue-selective Estrogen Complex for Menopausal Hormone Therapy. | Clinical Obstetrics and Gynecology | 2018 |
| 29894370 | Not time to abandon use of local vaginal hormone therapies. | Menopause | 2018 |
| 29762200 | Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. | Menopause | 2018 |
| 29658911 | Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women. | Menopause | 2018 |
| 29557848 | Hormonal contraception and risk of breast cancer: a closer look. | Menopause | 2018 |
| 29257034 | Screening mammography for average-risk women. | Menopause | 2018 |
| 29251683 | Menopause 25th anniversary: past success and future direction. | Menopause | 2018 |
| 29419532 | Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. | Clinical Obstetrics and Gynecology | 2018 |
| 29040220 | Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. | Menopause | 2017 |
| 28463874 | Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene. | Menopause | 2017 |
| 28763394 | Changing the conversation about hormone therapy. | Menopause | 2017 |
| 28675703 | Changing the conversation about hormone therapy. | Climacteric | 2017 |